A US patent titled 'Biomarkers for lung cancer stem cells' has been granted

 A US patent titled "Biomarkers for lung cancer stem cells"
has been granted

1.Date of occurrence of the event:2024/09/27
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
The Company has been informed by the patent agency that a United States
patent titled "BIOMARKERS FOR LUNG CANCER STEM CELLS" has been granted
under the patent number US 12,085,570 B2.
6.Countermeasures:None.
7.Any other matters that need to be specified(the information
 disclosure also meets the requirements of Article 7, subparagraph 9
 of the Securities and Exchange Act Enforcement Rules, which brings
 forth a significant impact on shareholders rights or the price of
 the securities on public companies.):
(1)This patent is for biomarkers for lung cancer stem cells which could be
   applied to cancer diagnosis and target patient screening. In addition,
   the expression of such biomarkers had been demonstrated to correlate with
   the prognosis of the patients, which predict the survival and recurrence
   in patents with the lung cancer.
(2)The patent is owned by National Taiwan University. Oneness has been
   exclusively authorized to use this patent and to manufacture, use and sell
   the products of this invention.